GH Research PLC
NASDAQ:GHRSBiotechnology
Healthcare
$18.25 -0.18%
-$0.04 today
- Market cap
- $1.25B
- Beta
- 1.31
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.91
52W Low $11.32High $25.94
Volume 0.46M
Average 0.23M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$43.55M
FY 2025 · Annual
Investing Cash Flow
$46.17M
FY 2025 · Annual
-29.1% YoYFinancing Cash Flow
$139.65M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Depreciation & Amortization | 19K | 47K | 315K | 315K | 335K |
| Deferred Income Tax | (5.92M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 366K | 1.67M | 2.29M | 1.17M | 0 |
| Change in Working Capital | (559K) | 2.16M | 1.65M | 188K | (3.09M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (559K) | 2.16M | 1.65M | 188K | (3.09M) |
| Other Non-Cash Items | 9K | (7.62M) | (2M) | (5M) | 7.46M |
| Operating Cash Flow | (15.28M) | (26.2M) | (33.34M) | (42.29M) | (43.55M) |
| Capital Expenditures | (104K) | (67K) | (100K) | (49K) | (121K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (84.62M) | (54M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 65.18M | 46.29M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (104K) | (84.69M) | (54.1M) | 65.14M | 46.17M |
| Debt Repayment | 0 | 0 | (219K) | (304K) | 0 |
| Common Stock Issued | 309.2M | 0 | 15K | 0 | 139.85M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22.75M) | 0 | 0 | 0 | (197K) |
| Financing Cash Flow | 286.45M | 0 | (204K) | (304K) | 139.65M |
| Effect of Forex Changes | (179K) | 66K | 105K | (175K) | 3.19M |
| Net Change in Cash | 270.88M | (110.82M) | (87.54M) | 22.37M | 145.46M |
| Free Cash Flow | (15.39M) | (26.27M) | (33.44M) | (42.33M) | (43.67M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$48.3M
+ D&A$335.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$3.1M
+ Other Non-Cash$7.5M
= Operating Cash Flow-$43.6M
- Capex-$121.0K
= Free Cash Flow-$43.7M
Analysis
FY2025 free cash flow is -$43.7M. FCF conversion is 90.5% of net income. Operating cash flow was -$43.6M, with capex of -$121.0K. The largest bridge item is Other Non-Cash at $7.5M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Oct 9, 2026 | |
| 6-K | 6-K filing | Sep 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 9, 2026 |
Does GHRS generate free cash flow?
GH Research PLC (GHRS) generated -$43.67M of free cash flow in fiscal 2025.
How much operating cash flow does GHRS produce?
Operating cash flow was -$43.55M, before capital expenditures of $121,000.00.
Continue the stock analysis
Jump to another research area for this company.